Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Debt Ratio (2020 - 2023)

C4 Therapeutics' Debt Ratio history spans 4 years, with the latest figure at 0.03 for Q2 2023.

  • For Q2 2023, Debt Ratio rose 22.03% year-over-year to 0.03; the TTM value through Jun 2023 reached 0.03, up 22.03%, while the annual FY2022 figure was 0.03, 25.42% up from the prior year.
  • Debt Ratio reached 0.03 in Q2 2023 per CCCC's latest filing, roughly flat from 0.03 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.04 in Q3 2020 to a low of 0.02 in Q2 2021.
  • Average Debt Ratio over 4 years is 0.03, with a median of 0.02 recorded in 2020.
  • Peak YoY movement for Debt Ratio: tumbled 51.64% in 2021, then increased 29.73% in 2023.
  • A 4-year view of Debt Ratio shows it stood at 0.03 in 2020, then decreased by 15.42% to 0.02 in 2021, then grew by 25.42% to 0.03 in 2022, then grew by 3.41% to 0.03 in 2023.
  • Per Business Quant, the three most recent readings for CCCC's Debt Ratio are 0.03 (Q2 2023), 0.03 (Q1 2023), and 0.03 (Q4 2022).